Genelux (GNLX) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Genelux (GNLX) has outperformed Humacyte (HUMA) over the past year, losing 47.4% versus a loss of 73.5%. Humacyte is the larger company by market cap ($124.2 million vs $113.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | HUMA |
|---|---|---|
| Share price | $2.50 | $0.4471 |
| Market cap | $113.11M | $124.20M |
| 1-day change | -0.79% | -5.34% |
| YTD return | -42.66% | -53.48% |
| 1-year return | -47.37% | -73.54% |
| 5-year return | — | -95.63% |
| EPS (TTM) | $-0.86 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $1.90 |
| 52-week low | $2.29 | $0.4367 |
| Distance from 52-week high | -70.71% | -76.41% |
| Analyst consensus | none | buy |
| Avg. price target upside | +653.20% | +264.57% |
| Average volume | 276.16K | 6.30M |
| Shares outstanding | 45.25M | 277.80M |
| Employees | 25 | 184 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GNLX has outperformed HUMA by 26.2 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Healthcare · Biotechnology · 25 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Healthcare · Biotechnology · 184 employees
GNLX vs HUMA FAQ
Which is bigger, Genelux or Humacyte?
Humacyte (HUMA) is larger, with a market capitalization of $124.20M compared with $113.11M for Genelux (GNLX).
Which stock has performed better over the past year, GNLX or HUMA?
GNLX returned -47.37% over the past 12 months, compared with -73.54% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Humacyte in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.